SQZ Biotech to Present at UBS Virtual Global Healthcare Conference

WATERTOWN, Mass.--()--SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that management will present a corporate overview at the UBS Virtual Global Healthcare Conference on May 18, 2020 at 10:50am EST.

The presentation will be available through the UBS Virtual Global Healthcare Conference webcast system linked here. Armon Sharei, PhD, chief executive officer, and Teri Loxam, chief financial officer, will also be hosting one-on-one meetings with investors through the virtual system.

About SQZ Biotech

SQZ Biotech is a privately held clinical stage company developing transformative cell therapy candidates for patients with cancer and other serious diseases. Our proprietary approach to cell engineering, Cell Squeeze®, physically squeezes cells through a microfluidic constriction to temporarily disrupt the cell membrane, allowing desired cargo to diffuse into the cell cytosol before the membrane reseals. We use this approach to deliver a broad range of biological material into diverse cell types to create multifunctional cell therapy candidates designed to direct specific immune responses. We believe Cell Squeeze® technology may allow us to create cost-effective and rapidly scalable cell therapies that leverage natural physiology to improve therapeutic efficacy, safety and tolerability relative to currently approved cell therapies. For more information please visit www.sqzbiotech.com.

Contacts

SQZ:
Rebecca Cohen
Corporate and Investor Relations
rebecca.cohen@sqzbiotech.com
617-758-8672 ext. 728

Media:
Kate Contreras
Associate Director
kcontreras@w2ogroup.com
617-229-5960

Contacts

SQZ:
Rebecca Cohen
Corporate and Investor Relations
rebecca.cohen@sqzbiotech.com
617-758-8672 ext. 728

Media:
Kate Contreras
Associate Director
kcontreras@w2ogroup.com
617-229-5960